Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Towards clinical translation of urinary vitronectin for non-invasive detection and monitoring of renal fibrosis in kidney transplant patients

  • Clos Sansalvador, Marta|||0000-0001-8522-7818
  • Taco, Omar|||0000-0001-9081-5665
  • Rodríguez-Martínez, Paula|||0000-0002-9001-2501
  • Garcia, Sergio G.|||0000-0001-7698-3734
  • Font-Morón, Miriam|||0000-0002-4714-252X
  • Bover, Jordi|||0000-0003-3577-2273
  • Vila-Santandreu, Anna
  • Franquesa, Marcella|||0000-0002-1287-8908
  • Juega-Mariño, Javier|||0000-0002-9927-9683
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
Interstitial fibrosis and tubular atrophy (IFTA) is a critical factor in the prognosis of kidney health. Currently, IFTA quantitation in kidney biopsy samples is crucial for diagnosis and assessing disease severity, but the available non-invasive biomarkers are not satisfactory. Proteomic studies identified urinary vitronectin (VTN) as a potential biomarker for kidney fibrosis. As mass spectrometry techniques are not practical for use in clinical settings, we tested whether evaluation of urinary VTN levels through enzyme-linked immunosorbent assay (ELISA) can help monitor fibrotic changes in kidney transplant recipients and prove the clinical viability of the assay. A total of 58 kidney transplant (KTx) patients who underwent renal biopsy were included in the study. Patients were categorized into two groups referred as no fibrosis (0%) or with fibrosis (≥ 5%) based on their histological findings. In a subsequent/follow-up analysis, the time elapsed from transplantation was also considered. The urinary levels of VTN were measured using ELISA. VTN (p = 0.0180) and VTN normalized by urinary creatinine levels (p = 0.0037), were significantly increased in patients with fibrotic grafts. When focusing on patients with long-term grafts (> 3 years from transplantation, n = 36), VTN exhibited superior potential in identifying fibrotic grafts compared to albuminuria (VTN p = 0.0040 vs. albuminuria p = 0.0132). Importantly, in this group, while albuminuria correctly identified 71% of fibrotic patients, the combination of VTN plus albuminuria correctly classified 89% of fibrotic grafts detected by renal biopsy. VTN has emerged as a valid indicator of renal fibrosis. Of interest, urinary levels of VTN in combination with conventional clinical parameters (such as albuminuria) significantly improved the non-invasive detection of renal fibrosis in kidney transplant patients. The online version contains supplementary material available at 10.1186/s12967-024-05777-5.
Repisalud
Publication Artículo científico (JournalArticle)

Protein kinase D2 modulates hepatic insulin sensitivity in male mice.

  • Rada, Patricia
  • Carceller-López, Elena
  • Hitos, Ana B
  • Gómez-Santos, Beatriz
  • Fernández-Hernández, Constanza
  • Rey, Esther
  • Pose-Utrilla, Julia
  • García-Monzón, Carmelo
  • González-Rodríguez, Águeda
  • Sabio, Guadalupe
  • García, Antonia
  • Aspichueta, Patricia
  • Iglesias, Teresa
  • Valverde, Ángela M
Protein kinase D (PKD) family is emerging as relevant regulator of metabolic homeostasis. However, the precise role of PKD2 in modulating hepatic insulin signaling has not been fully elucidated and it is the aim of this study. PKD inhibition was analyzed for insulin signaling in mouse and human hepatocytes. PKD2 was overexpressed in Huh7 hepatocytes and mouse liver, and insulin responses were evaluated. Mice with hepatocyte-specific PKD2 depletion (PKD2) and PKD2 mice were fed a chow (CHD) or high fat diet (HFD) and glucose homeostasis and lipid metabolism were investigated. PKD2 silencing enhanced insulin signaling in hepatocytes, an effect also found in primary hepatocytes from PKD2 mice. Conversely, a constitutively active PKD2 mutant reduced insulin-stimulated AKT phosphorylation. A more in-depth analysis revealed reduced IRS1 serine phosphorylation under basal conditions and increased IRS1 tyrosine phosphorylation in PKD2 primary hepatocytes upon insulin stimulation and, importantly PKD co-immunoprecipitates with IRS1. In vivo constitutively active PKD2 overexpression resulted in a moderate impairment of glucose homeostasis and reduced insulin signaling in the liver. On the contrary, HFD-fed PKD2 male mice displayed improved glucose and pyruvate tolerance, as well as higher peripheral insulin tolerance and enhanced hepatic insulin signaling compared to control PKD2 mice. Despite of a remodeling of hepatic lipid metabolism in HFD-fed PKD2 mice, similar steatosis grade was found in both genotypes. Results herein have unveiled an unknown role of PKD2 in the control of insulin signaling in the liver at the level of IRS1 and point PKD2 as a therapeutic target for hepatic insulin resistance.
Investigo. Repositorio Institucional de la Universidade de Vigo
Publication Artículo científico (JournalArticle)

Comparative analysis of capture methods for genomic profiling of circulating tumor cells in colorectal cancer

  • Fernandes Alves, Joao Miguel
  • Estevez Gomez, Nuria
  • Valecha , Monica Vishnu
  • Prado López, Sonia
  • Tomás López, Laura
  • Alvariño Sanjurjo, Pilar
  • Silva Piñeiro, Roberto
  • Muinelo Romay, Laura
  • Mondelo Macía, Patricia
  • Salgado, Mercedes
  • Iglesias Gómez, Agueda
  • Codesido Prada, Laura
  • Cubiella Fernández, Joaquín
  • Posada González, David
Financiado para publicación en acceso aberto: Universidade de Vigo/CISUG, The genomic profiling of circulating tumor cells (CTCs) in the bloodstream should provide clinically relevant information on therapeutic efficacy and help predict cancer survival. Here, we contrasted the genomic profiles of CTC pools recovered from metastatic colorectal cancer (mCRC) patients using different enrichment strategies (CellSearch, Parsortix, and FACS). Mutations inferred in the CTC pools differed depending on the enrichment strategy and, in all cases, represented a subset of the mutations detected in the matched primary tumor samples. However, the CTC pools from Parsortix, and in part, CellSearch, showed diversity estimates, mutational signatures, and drug-suitability scores remarkably close to those found in matching primary tumor samples. In addition, FACS CTC pools were enriched in apparent sequencing artifacts, leading to much higher genomic diversity estimates. Our results highlight the utility of CTCs to assess the genomic heterogeneity of individual tumors and help clinicians prioritize drugs in mCRC., Agencia Estatal de Investigación | Ref. PID2019-106247GB-I00, Xunta de Galicia | Ref. ED481A-2018/303, Instituto de Salud Carlos III | Ref. PI17/00837, Instituto de Salud Carlos III | Ref. PI21/01771, Axencia Galega de Innovación | Ref. N607B-2020/02, Axencia Galega de Innovación | Ref. IN853B 2018/03
Investigo. Repositorio Institucional de la Universidade de Vigo
Publication Artículo científico (JournalArticle)

Optimal diagnostic accuracy of quantitative faecal immunochemical test positivity thresholds for colorectal cancer detection in primary health care: a community‐based cohort study

  • Pin Vieito, Noel
  • García Nimo, Laura
  • Bujanda, Luis
  • Román Alonso, Begoña
  • Gutiérrez Stampa, María Ángeles
  • Aguilar Gama, Vanessa
  • Portillo, Isabel
  • Cubiella Fernández, Joaquín
Background Optimizing colonoscopy resources is challenging, and information regarding performing diagnostic quantitative faecal immunochemical test (FIT) in daily clinical practice in primary health care is still limited. This study aimed to assess the sensitivity, specificity, positive predictive value and negative predictive value of varying FIT positivity thresholds on colorectal cancer (CRC) detection in primary health care. Methods A retrospective cohort study of 38,675 asymptomatic and symptomatic patients with a FIT (OC-Sensor™) performed between 2012 and 2016 in a primary health-care setting, using a clinical laboratory database of two Spanish areas linked with the National Health System's Hospital Discharge Records Database. The primary outcome was 2-year CRC incidence. Results The mean age of the participants was 63.2 years; 17,792 (46.0%) were male. CRC prevalence was 1.7% (650/38,675). The percentage of patients with a FIT result above the threshold was 20.7% and 14.6% for 10 μg Hb/g faeces and 20 μg Hb/g faeces thresholds, respectively. Sensitivity was 90.5% (95% confidence interval 88.0%–92.5%) at a 10 μg Hb/g faeces threshold, and this decreased by 3.1% when a 20 μg Hb/g faeces threshold was used. The negative predictive value for CRC was at least 99.2% in any subgroup analysed. At a 20 μg Hb/g faeces threshold, less than one additional CRC would be missed per 1000 patients investigated, while approximately 1.3 times more colonoscopy examinations were needed to identify an incidence of CRC using the lowest threshold for any situation analysed. Conclusions In primary health care, a quantitative FIT threshold should be tailored to colonoscopy capacity and CRC prevalence in specific populations., Instituto de Salud Carlos III, España | Ref. PI17/00837
Investigo. Repositorio Institucional de la Universidade de Vigo
Publication Artículo científico (JournalArticle)

Predictive value of carcinoembryonic antigen in symptomatic patients without colorectal cancer: A post-hoc analysis within the COLONPREDICT cohort

  • Pin Vieito, Noel
  • Iglesias, María José
  • Remedios, David
  • Álvarez Sánchez, Patricia
  • Fernández Bañares, Fernando
  • Boadas, Jaume
  • Martínez Bauer, Eva
  • Campo, Rafael
  • Bujanda, Luis
  • Ferrández, Ángel
  • Piñol, Virginia
  • Rodríguez Alcalde, Daniel
  • Menéndez Rodríguez, Martín
  • García Morales, Natalia
  • Pérez Mosquera, Cristina
  • Cubiella Fernández, Joaquín
We aimed to assess the risk of cancer in patients with abdominal symptoms after a complete colonoscopy without colorectal cancer (CRC), according to the carcinoembryonic antigen (CEA) concentration, as well as its diagnostic accuracy. For this purpose, we performed a post-hoc analysis within a cohort of 1431 patients from the COLONPREDICT study, prospectively designed to assess the fecal immunochemical test accuracy in detecting CRC. Over 36.5 ± 8.4 months, cancer was detected in 115 (8%) patients. Patients with CEA values higher than 3 ng/mL revealed an increased risk of cancer (HR 2.0, 95% CI 1.3–3.1), CRC (HR 4.4, 95% CI 1.1–17.7) and non-gastrointestinal cancer (HR 1.7, 95% CI 1.0–2.8). A new malignancy was detected in 51 (3.6%) patients during the first year and three variables were independently associated: anemia (OR 2.8, 95% CI 1.3–5.8), rectal bleeding (OR 0.3, 95% CI 0.1–0.7) and CEA level >3 ng/mL (OR 3.4, 95% CI 1.7–7.1). However, CEA was increased only in 31.8% (95% CI, 16.4–52.7%) and 50% (95% CI, 25.4–74.6%) of patients with and without anemia, respectively, who would be diagnosed with cancer during the first year of follow-up. On the basis of this information, CEA should not be used to assist in the triage of patients presenting with lower bowel symptoms who have recently been ruled out a CRC., Instituto de Salud Carlos III, España | Ref. PI17/00837
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Retrospective cohort study: Risk of gastrointestinal cancer in a symptomatic cohort after a complete colonoscopy: Role of faecal immunochemical test

  • Pin-Vieito, N.
  • Iglesias, M. J.
  • Remedios, D.
  • Rodríguez-Alonso, L.
  • Rodriguez-Moranta, F.
  • Álvarez-Sánchez, V.
  • Fernández-Bañares, F.
  • Boadas, J.
  • Martínez-Bauer, E.
  • Campo, R.
  • Bujanda, L.
  • Ferrandez, Á.
  • Piñol, V.
  • Rodríguez-Alcalde, D.
  • Guardiola, J.
  • Cubiella, J.
  • González-López, N.
  • Quintero, E.
  • Bañales, J.
  • Bujanda, L.
  • Perugorria, M. J.
  • Cleries, R.
  • Ribes, J.
  • Sanz, X.
  • López-Vicente, J.
  • Rodriguez-Alcalde, D.
  • Piñol, V.
  • Torrealba, L.
  • Blanco, I.
  • Cubiella, J.
  • Díaz-Ondina, M.
  • Salve, M.
  • Fernández-Seara, J.
  • Iglesias, M. J.
  • Macía, P.
  • Remedios, D.
  • Sánchez, E.
  • Vega, P.
  • Campo, R.
  • Martínez-Bauer, E.
  • Pujol, M.
  • Sánchez, V. Á.
  • Mera, J.
  • Turnes, J.
  • Clofent, J.
  • Garayoa, A.
  • Fernández-Bañares, F.
  • Gonzalo, V.
  • Pujals, M.
  • Boadas, J.
  • Galter, S.
  • Garcia-Lanuza, E.
  • Gimeno, R.
  • Alsius, A.
  • Ferrández, Á.
  • Sánchez, M. S.
BACKGROUND: Faecal immunochemical test (FIT) has been recommended to assess symptomatic patients for colorectal cancer (CRC) detection. Nevertheless, some conditions could theoretically favour blood originating in proximal areas of the gastrointestinal tract passing through the colon unmetabolized. A positive FIT result could be related to other gastrointestinal cancers (GIC). AIM: To assess the risk of GIC detection and related death in FIT-positive symptomatic patients (threshold 10 µg Hb/g faeces) without CRC. METHODS: Post hoc cohort analysis performed within two prospective diagnostic test studies evaluating the diagnostic accuracy of different FIT analytical systems for CRC and significant colonic lesion detection. Ambulatory patients with gastrointestinal symptoms referred consecutively for colonoscopy from primary and secondary healthcare, underwent a quantitative FIT before undergoing a complete colonoscopy. Patients without CRC were divided into two groups (positive and negative FIT) using the threshold of 10 µg Hb/g of faeces and data from follow-up were retrieved from electronic medical records of the public hospitals involved in the research. We determined the cumulative risk of GIC, CRC and upper GIC. Hazard rate (HR) was calculated adjusted by age, sex and presence of significant colonic lesion. RESULTS: We included 2709 patients without CRC and a complete baseline colonoscopy, 730 (26.9%) with FIT = 10 µgr Hb/gr. During a mean time of 45.5 ± 20.0 mo, a GIC was detected in 57 (2.1%) patients: An upper GIC in 35 (1.3%) and a CRC in 14 (0.5%). Thirty-six patients (1.3%) died due to GIC: 22 (0.8%) due to an upper GIC and 9 (0.3%) due to CRC. FIT-positive subjects showed a higher CRC risk (HR 3.8, 95%CI: 1.2-11.9) with no differences in GIC (HR 1.5, 95%CI: 0.8-2.7) or upper GIC risk (HR 1.0, 95%CI: 0.5-2.2). Patients with a positive FIT had only an increased risk of CRC-related death (HR 10.8, 95%CI: 2.1-57.1) and GIC-related death (HR 2.2, 95%CI: 1.1-4.3), with no differences in upper GIC-related death (HR 1.4, 95%CI: 0.6-3.3). An upper GIC was detected in 22 (0.8%) patients during the first year. Two variables were independently associated: anaemia (OR 5.6, 95%CI: 2.2-13.9) and age = 70 years (OR 2.7, 95%CI: 1.1-7.0). CONCLUSION: Symptomatic patients without CRC have a moderate risk increase in upper GIC, regardless of the FIT result. Patients with a positive FIT have an increased risk of post-colonoscopy CRC.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Predictive Value of Carcinoembryonic Antigen in Symptomatic Patients without Colorectal Cancer: A Post-Hoc Analysis within the COLONPREDICT Cohort

  • Pin-Vieito, N.
  • Iglesias, M.J.
  • Remedios, D.
  • Alvarez-Sanchez, V.
  • Fernandez-Banares, F.
  • Boadas, J.
  • Martinez-Bauer, E.
  • Campo, R.
  • Bujanda, L.
  • Ferrandez, A.
  • Pinol, V.
  • Rodriguez-Alcalde, D.
  • Menendez-Rodriguez, M.
  • Garcia-Morales, N.
  • Perez-Mosquera, C.
  • Cubiella, J.
We aimed to assess the risk of cancer in patients with abdominal symptoms after a complete colonoscopy without colorectal cancer (CRC), according to the carcinoembryonic antigen (CEA) concentration, as well as its diagnostic accuracy. For this purpose, we performed a post-hoc analysis within a cohort of 1431 patients from the COLONPREDICT study, prospectively designed to assess the fecal immunochemical test accuracy in detecting CRC. Over 36.5 +/- 8.4 months, cancer was detected in 115 (8%) patients. Patients with CEA values higher than 3 ng/mL revealed an increased risk of cancer (HR 2.0, 95% CI 1.3-3.1), CRC (HR 4.4, 95% CI 1.1-17.7) and non-gastrointestinal cancer (HR 1.7, 95% CI 1.0-2.8). A new malignancy was detected in 51 (3.6%) patients during the first year and three variables were independently associated: anemia (OR 2.8, 95% CI 1.3-5.8), rectal bleeding (OR 0.3, 95% CI 0.1-0.7) and CEA level >3 ng/mL (OR 3.4, 95% CI 1.7-7.1). However, CEA was increased only in 31.8% (95% CI, 16.4-52.7%) and 50% (95% CI, 25.4-74.6%) of patients with and without anemia, respectively, who would be diagnosed with cancer during the first year of follow-up. On the basis of this information, CEA should not be used to assist in the triage of patients presenting with lower bowel symptoms who have recently been ruled out a CRC.
Docta Complutense
Publication Artículo científico (JournalArticle)

Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study

  • Rial Crestelo, David
  • Rubio García, Rafael
  • Delgado Vázquez, Rafael
  • Pulido Ortega, Federico
  • Arribas JR
Background: In the ART-PRO pilot trial there were no virological failures through 48 weeks of treatment with dolutegravir plus lamivudine in suppressed individuals with and without archived lamivudine resistance-associated mutations (RAMs) detected through next-generation sequencing (NGS) but without evidence of lamivudine RAMs in baseline proviral DNA population sequencing. Objectives: To present 96 week results from ART-PRO. Methods: Open-label, single-arm pilot trial. At baseline, all participants switched to dolutegravir plus lamivudine. Participants were excluded if proviral DNA population genotyping detected lamivudine RAMs. To detect resistance minority variants, proviral DNA NGS was retrospectively performed from baseline samples. For this analysis the efficacy endpoint was the proportion of participants with <50 HIV-1 RNA copies/mL at week 96. Safety and tolerability outcomes were incidence of adverse events and treatment discontinuations. Results: Forty-one participants were included, 21 with lamivudine RAMs in historical plasma RNA genotypes. Baseline proviral DNA NGS detected lamivudine RAMs (M184V/I and/or K65R/E/N) above a 5% threshold in 71.4% (15/21) and 15% (3/20) of participants with and without history of lamivudine resistance, respectively. At 96 weeks, 90.2% of participants achieved the efficacy endpoint. Between week 48 and 96 there was one discontinuation due to consent withdrawal and no discontinuations related to adverse events. Two participants had a transient viral rebound, both re-suppressed on dolutegravir plus lamivudine. Through week 96, there were no virological failures. Conclusions: In this pilot trial, dolutegravir plus lamivudine maintained virological suppression at 96 weeks despite historical lamivudine resistance and persisting archived minority lamivudine RAMs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Transcriptome Analysis of Ullrich Congenital Muscular Dystrophy Fibroblasts Reveals a Disease Extracellular Matrix Signature and Key Molecular Regulators

  • Paco Mercader, Sonia|||0000-0002-7151-8144
  • Casserras, Teresa
  • Rodríguez, Maria Angels
  • Jou, Cristina|||0000-0002-2223-7880
  • Puigdelloses, Montserrat
  • Ortez González, Carlos Ignacio|||0000-0001-8187-8103
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Colomer, Jaume
  • Nascimento, Andrés
  • Kalko, Susana G.|||0000-0002-6701-0233
  • Jiménez Mallebrera, Cecilia|||0000-0001-8203-7103
Collagen VI related myopathies encompass a range of phenotypes with involvement of skeletal muscle, skin and other connective tissues. They represent a severe and relatively common form of congenital disease for which there is no treatment. Collagen VI in skeletal muscle and skin is produced by fibroblasts. In order to gain insight into the consequences of collagen VI mutations and identify key disease pathways we performed global gene expression analysis of dermal fibroblasts from patients with Ullrich Congenital Muscular Dystrophy with and without vitamin C treatment. The expression data were integrated using a range of systems biology tools. Results were validated by real-time PCR, western blotting and functional assays. We found significant changes in the expression levels of almost 600 genes between collagen VI deficient and control fibroblasts. Highly regulated genes included extracellular matrix components and surface receptors, including integrins, indicating a shift in the interaction between the cell and its environment. This was accompanied by a significant increase in fibroblasts adhesion to laminin. The observed changes in gene expression profiling may be under the control of two miRNAs, miR-30c and miR-181a, which we found elevated in tissue and serum from patients and which could represent novel biomarkers for muscular dystrophy. Finally, the response to vitamin C of collagen VI mutated fibroblasts significantly differed from healthy fibroblasts. Vitamin C treatment was able to revert the expression of some key genes to levels found in control cells raising the possibility of a beneficial effect of vitamin C as a modulator of some of the pathological aspects of collagen VI related diseases.